Hormonal
Discontinuation of GLP-1 therapy leads to significant weight regain (up to two-thirds of lost weight within 1 year), highlighting the necessity of long-term lifestyle interventions and potentially long-term medication use.
Understand that GLP-1 therapy is likely a long-term treatment for obesity. If you stop the medication, you will likely regain a significant portion of your lost weight. Work with your provider to determine if you should stay on the medication long-term or transition to a maintenance strategy that includes intensive lifestyle support.
When GLP-1s are discontinued, weight regain is common—with up to two-thirds of the lost weight regained within 1 years [18–20]. Notably, this has been observed even with accompanying use of conventional nutritional counseling and/or behavioral therapy [18, 19].
Why this rating
Based on multiple observational studies and clinical trials showing consistent weight regain patterns upon discontinuation.
Source
Nutritional priorities to support <scp>GLP</scp>‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society
Dariush Mozaffarian et al. · Obesity · 2025
DOI 10.1002/oby.24336
More from this paper
- GLP-1 receptor agonists for obesity treatment cause significant loss of lean body mass (including muscle) and bone density, with muscle loss accounting for approximately 20% of total weight reduction in the absence of structured resistance training.Good
- Rapid and substantial weight reduction via GLP-1 therapy increases the risk of nutrient deficiencies and bone density loss, particularly when caloric intake drops below 1200 kcal/day for females or 1800 kcal/day for males without nutritional counseling.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →